Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

88
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action.

PloS one·2021
Same author

A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.

PloS one·2017
Same author

Steroidal alkaloids from the marine sponge Corticium niger that inhibit growth of human colon carcinoma cells.

Journal of natural products·2014
Same author

A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.

PloS one·2013
Same author

Bioinformatic analysis of patient-derived ASPS gene expressions and ASPL-TFE3 fusion transcript levels identify potential therapeutic targets.

PloS one·2012
Same author

Integrating constitutive gene expression and chemoactivity: mining the NCI60 anticancer screen.

PloS one·2012

Related Experiment Video

Updated: Apr 7, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K

Data Mining Approaches for Genomic Biomarker Development: Applications Using Drug Screening Data from the Cancer

David G Covell1

  • 1Screening Technologies Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, Maryland, United States of America.

Plos One
|July 2, 2015
PubMed
Summary

This study validates genomic biomarkers for predicting tumor drug response, confirming existing findings and revealing new insights. These biomarkers enhance hypothesis-driven research and clinical decisions for cancer treatment.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

7.1K

Related Experiment Videos

Last Updated: Apr 7, 2026

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases
07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

9.7K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

8.1K
Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres
06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

7.1K

Area of Science:

  • Oncology
  • Genomics
  • Biomarker Discovery

Background:

  • Reliable biomarkers for tumor cell drug sensitivity and resistance are crucial for guiding research and clinical decisions.
  • Existing biomarker strategies often correlate genomic changes with cancer drug responses, notably from the Cancer Cell Line Encyclopedia (CCLE) and Sanger Cancer Genome Project (CGP).

Purpose of the Study:

  • To independently analyze CCLE and CGP data for vetting existing and discovering novel biomarker perspectives.
  • To enhance the understanding of genomic biomarkers in predicting tumor drug sensitivity and resistance.

Main Methods:

  • Utilized data mining and statistical methods to analyze drug responses based on mechanism of action (MOA).
  • Examined gene expression (GE), copy number (CN), and mutation status (MUT) as biomarkers, incorporating gene set enrichment analysis (GSEA).
  • Conducted global comparisons of GE, CN, and MUT biomarkers across the CGP dataset and assessed the predictive power of CGP-derived GE biomarkers in CCLE cells.

Main Results:

  • Confirmed existing and identified unique/shared roles of GE, MUT, and CN biomarkers in tumor drug sensitivity and resistance.
  • CGP-derived genomic biomarkers demonstrated significant predictive power (ROC, 0.78 positive predictive value) for CCLE tumor cell drug response.
  • Validated the utility of genomic biomarkers in predicting drug response across different datasets.

Conclusions:

  • The study expands data mining and analysis methods for genomic biomarker development.
  • Provides further support for utilizing biomarkers to direct hypothesis-driven basic science research.
  • Reinforces the application of biomarkers in informing pre-therapy clinical decisions for cancer treatment.